Close X
Get more out of
by joining the site for free
Free 17-point plan to great health
Twice weekly e-news bulletins
Access to our News, Forums and Blogs
Sign up for free and claim your
17-point plan to great health
Free 17-point plan to great health

Twice weekly e-news bulletins

Access to our News, Forums and Blogs

If you want to read our in-depth research articles or
have our amazing magazine delivered to your home
each month, then you have to pay.

Click here if you're interested
Helping you make better health choices

In shops now or delivered to your home from only £3.50 an issue!


China refuses to release safety record of HPV vaccine ahead of national launch
About the author: 
Bryan Hubbard

China’s drug regulator is refusing to release the safety reports on the Cervarix HPV vaccine ahead of the drug’s national launch next year.

The vaccine, manufactured by GlaxoSmithKline (GSK), is to be made available to all girls in China aged from nine years in 2017. It is designed to prevent cervical cancer.

Ahead of the launch, it was tested on 6,000 Chinese girls—but authorities are refusing to release the toxicology reports and clinical trial data that would reveal any side effects and adverse reactions suffered by the girls.

Activists in Beijing requested China’s drug regulator, the Chinese State Bureau of Food & Drug Supervisory Administration, to release the data last July, but the bureau has refused to do so, on the grounds that it “involves enterprise commercial secrets”—in other words, because the results are a trade secret.

One reason for the secrecy could be because the trial wasn’t properly constructed, and the vaccine was never tested against an inert placebo. As a result, adverse reactions could be experienced by those given the vaccine or the placebo, so reducing the risk profile of the vaccine itself.

The decision is unprecedented in developed countries, where safety takes precedence over trade secrecy. It also goes against the policies of the Healthy China initiative, set out by China’s chairman Xi Jin-ping, says researcher Cen I-wan.

China’s drug regulator has also received a request from pathologist Dr Sin Hang Lee to rethink its decision to grant its approval for Cervarix’s launch. Dr Lee, who studied in China but now lives in the US, says the HPV vaccines haven’t prevented even one case of cervical cancer, and yet had been associated with tens of thousands of reports of adverse reactions in young girls, ranging from nervous disorders, chronic disabilities and even death.


(Source: SaneVax Inc)

You may also be interested in...

Latest Tweet


Since 1989, WDDTY has provided thousands of resources on how to beat asthma, arthritis, depression and many other chronic conditions.

Start by looking in our fully searchable database, active and friendly community forums and the latest health news.

Positive SSL Wildcard

Facebook Twitter

Most Popular Health Website of the Year 2014

© 2010 - 2017 WDDTY Publishing Ltd.
All Rights Reserved